Janney Montgomery Scott began coverage on shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in a research note issued to investors on Friday, MarketBeat.com reports. The brokerage issued a neutral rating and a $47.00 price target on the specialty pharmaceutical company’s stock.
SUPN has been the subject of a number of other reports. BidaskClub upgraded Supernus Pharmaceuticals from a buy rating to a strong-buy rating in a report on Saturday, June 24th. Jefferies Group LLC set a $35.00 price objective on Supernus Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, May 10th. Zacks Investment Research upgraded Supernus Pharmaceuticals from a hold rating to a buy rating and set a $49.00 price objective for the company in a report on Thursday. Cowen and Company upped their price objective on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the stock an outperform rating in a report on Thursday, May 11th. Finally, Cantor Fitzgerald upped their price objective on Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a buy rating in a report on Wednesday, July 5th. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $42.00.
Supernus Pharmaceuticals (NASDAQ:SUPN) traded down 5.20% during midday trading on Friday, reaching $41.95. The company’s stock had a trading volume of 1,366,935 shares. The stock has a market capitalization of $2.11 billion, a PE ratio of 22.57 and a beta of 1.34. The firm’s 50-day moving average price is $38.15 and its 200-day moving average price is $30.48. Supernus Pharmaceuticals has a 52 week low of $17.25 and a 52 week high of $44.95.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.22 by $0.03. The firm had revenue of $57.58 million for the quarter, compared to analyst estimates of $57.91 million. Supernus Pharmaceuticals had a return on equity of 31.79% and a net margin of 42.46%. On average, analysts anticipate that Supernus Pharmaceuticals will post $1.01 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Coverage Initiated by Analysts at Janney Montgomery Scott” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/07/17/supernus-pharmaceuticals-inc-nasdaqsupn-coverage-initiated-by-analysts-at-janney-montgomery-scott.html.
In related news, CFO Gregory S. Patrick sold 54,000 shares of the stock in a transaction on Monday, April 24th. The stock was sold at an average price of $32.37, for a total value of $1,747,980.00. Following the completion of the sale, the chief financial officer now directly owns 54,221 shares in the company, valued at approximately $1,755,133.77. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 11,806 shares of the stock in a transaction on Monday, April 24th. The shares were sold at an average price of $32.59, for a total value of $384,757.54. Following the completion of the sale, the vice president now owns 45,500 shares of the company’s stock, valued at $1,482,845. The disclosure for this sale can be found here. Over the last quarter, insiders sold 90,097 shares of company stock valued at $3,095,503. 6.70% of the stock is owned by insiders.
Hedge funds have recently made changes to their positions in the stock. Meeder Asset Management Inc. increased its stake in shares of Supernus Pharmaceuticals by 3,455.2% in the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 2,315 shares in the last quarter. Ameritas Investment Partners Inc. bought a new stake in shares of Supernus Pharmaceuticals during the first quarter valued at about $127,000. Fortaleza Asset Management Inc. bought a new stake in shares of Supernus Pharmaceuticals during the first quarter valued at about $160,000. State of Alaska Department of Revenue increased its stake in shares of Supernus Pharmaceuticals by 3.2% in the first quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 170 shares in the last quarter. Finally, OppenheimerFunds Inc. bought a new stake in shares of Supernus Pharmaceuticals during the first quarter valued at about $205,000. Hedge funds and other institutional investors own 90.95% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.